Tranche Update on REYON Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 6, 2018.
January 06, 2019
Share
From October 1, 2018 to January 5, 2019, the company has repurchased 5,500 shares, representing 0.03% for KRW 105.35 million. With this, the company has completed the repurchase of 240,840 shares, representing 1.44% for KRW 4,975.65 million under the buyback announced on July 6, 2018.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 
